Design Therapeutics (DSGN) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Design Therapeutics (DSGN) over the past year, gaining 278.1% versus a gain of 80.1%. Immix Biopharma is the larger company by market cap ($757.7 million vs $699.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | IMMX |
|---|---|---|
| Share price | $11.17 | $9.14 |
| Market cap | $699.04M | $757.73M |
| 1-day change | -4.45% | -3.69% |
| YTD return | +24.63% | +81.45% |
| 1-year return | +80.12% | +278.09% |
| 5-year return | -17.96% | — |
| EPS (TTM) | $-1.18 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $15.10 |
| 52-week low | $5.28 | $2.31 |
| Distance from 52-week high | -35.25% | -39.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +94.36% | +165.86% |
| Average volume | 603.58K | 1.65M |
| Shares outstanding | 62.58M | 82.90M |
| Employees | 55 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed DSGN by 198.0 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
DSGN vs IMMX FAQ
Which is bigger, Design Therapeutics or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $757.73M compared with $699.04M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or IMMX?
IMMX returned +278.09% over the past 12 months, compared with +80.12% for DSGN (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.